A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Purpose
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate medical problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.
Condition
- Crohn's Disease
Eligibility
- Eligible Ages
- Between 18 Years and 75 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Male or female aged 18-75 years old with diagnosis of CD for at least 30 days. In South Korea, the age requirement for adult participants is >=19 years of age. 2. Confirmed diagnosis of moderately to severely active CD assessed by SES-CD and CDAI. 3. Participants must have had an inadequate response to, loss of response to, or intolerance to at least one or more conventional, biologic, or advanced therapy for CD.
Exclusion Criteria
- Participants with indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, and diverticular disease associated with colitis, and/or ulcerative colitis. 2. Have complications of CD that might require surgery during the study. 3. Participants with a current ostomy. 4. Participants who have failed 3 or more classes of advanced therapies.
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental TAK-279 Dose 1 |
Participants will be randomized to receive TAK-279 Dose 1 capsules with TAK-279 placebo-matching capsule orally. |
|
|
Experimental TAK-279 Dose 2 |
Participants will be randomized to receive TAK-279 Dose 2 capsules with TAK-279 placebo-matching capsule orally. |
|
|
Experimental TAK-279 Dose 3 |
Participants will be randomized to receive TAK-279 Dose 3 capsules orally. |
|
|
Experimental Placebo |
Participants will be randomized to receive TAK-279 placebo-matching capsules orally. |
|
Recruiting Locations
Los Angeles 5368361, California 5332921 90067
Murrieta 5375911, California 5332921 92563
Orange 5379513, California 5332921 92868
Clearwater 4151316, Florida 4155751 33762
Lakeland 4161438, Florida 4155751 33813
Miami Lakes 4164186, Florida 4155751 33016
Naples 4165565, Florida 4155751 34102
Tampa 4174757, Florida 4155751 33612
Atlanta 4180439, Georgia 4197000 30322
Decatur 4191124, Georgia 4197000 30033
Iowa City 4862034, Iowa 4862182 52242
Louisville 4299276, Kentucky 6254925 40202
Glen Burnie 4356188, Maryland 4361885 21061
Liberty 4395052, Missouri 4398678 64068
Las Vegas 5506956, Nevada 5509151 89128
New York 5128581, New York 5128638 10029
Rochester 5134086, New York 5128638 14609
Mentor 5162645, Ohio 5165418 44060
Providence 5224151, Rhode Island 5224323 02904
Greenville 4580543, South Carolina 4597040 29615
Bellaire 4673353, Texas 4736286 77401
Dallas 4684888, Texas 4736286 75246
Fort Worth 4691930, Texas 4736286 76104
Mansfield 4709013, Texas 4736286 76063
San Antonio 4726206, Texas 4736286 78229
Tyler 4738214, Texas 4736286 75701
Seattle 5809844, Washington 5815135 98195
More Details
- NCT ID
- NCT06233461
- Status
- Recruiting
- Sponsor
- Takeda
Detailed Description
The drug being tested in this study is TAK-279. TAK-279 is being tested to treat participants with moderately to severely active Crohn's disease. The study will look at the efficacy and safety of TAK-279. The study will enroll approximately 268 participants. During the Induction Period participants will be randomly assigned to one of the following treatment groups in a ratio of 1:1:1:1 to receive TAK-279 or placebo which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need): 1. TAK-279 Dose 1 2. TAK-279 Dose 2 3. TAK-279 Dose 3 4. Placebo This multi-center trial will be conducted globally. The overall study duration is approximately 60 weeks including a 4-week safety follow-up period.